0.50Open0.50Pre Close0 Volume10 Open Interest2.00Strike Price0.00Turnover3050.13%IV-13.64%PremiumJul 19, 2024Expiry Date0.68Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8852Delta0.4789Gamma1.89Leverage Ratio-1.0393Theta0.0000Rho-1.67Eff Leverage0.0000Vega
Aclaris Therapeutics Stock Discussion
On July 19, 2024, Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, announced the sale of a portion of its future royalty payments and certain milestones related to OLUMIANT® (baricitinib) to OMERS...
Aclaris Therapeutics Shares Are Trading Higher After the Company Announced the Sale of OLUMIANT Royalties and Milestones to OMERS Life Sciences for up to $31.5 Million
Aclaris Therapeutics Inc - Receives $26.5M Upfront Payment
Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
Aclaris Therapeutics (NASDAQ: ACRS) has announced the sale of a portion of its future royalty payments and certain milestones for OLUMIANT® (baricitinib) to OMERS Life Sciences for up to $31.5 million. The deal includes a $26.5 million upfront payment and up to $5.0 million in potential milestone payments based on OLUMIANT sales in 2024. Thi...
No comment yet